BiotechTube
Home/Pipeline/Undisclosed Biosimilar

Undisclosed Biosimilar

Autoimmune Diseases

DevelopmentActive

Key Facts

Indication
Autoimmune Diseases
Phase
Development
Status
Active
Company
Polpharma Biologics

About Polpharma Biologics

Polpharma Biologics, originally founded in 2012 and headquartered in the Netherlands, has undergone a significant transformation, splitting into two independent entities. The remaining Polpharma Biologics is now a pure-play biosimilars developer with a strategic base in Zug, Switzerland, focusing on building a targeted pipeline and forging global partnerships. The company has a commercial-stage asset, Tyruko®, and leverages an agile development model aimed at accelerating biosimilar approval and market access. Its former large-scale manufacturing and CDMO operations now reside with the separate company, Rezon Bio, based in Poland.

View full company profile

Therapeutic Areas

OphthalmologyNeurologyImmunologyAutoimmune Diseases

Other Autoimmune Diseases Drugs

DrugCompanyPhase
Humira (Adalimumab) BiosimilarNeuCloneEarly Preclinical
HBM7020Harbour BioMedDiscovery
R2006Harbour BioMedDiscovery
R7027Harbour BioMedDiscovery
ImmCelz™ PlatformCreative Medical Technology HoldingsPreclinical
Not specified in provided content3SbioVarious
Gavocabtagene autoleucelastellasPhase 1/2
TYK-101TYK MedicinesPhase 1
HCB206HanchorBioPreclinical
miR-124 ActivatorFormation BioPhase 2
Autologous Cell Therapy CollaborationLupagenPreclinical
Autoimmune Diagnostics Leadership InitiativeVibrant America Clinical LaboratoryCommercial